Awareness of CPP within the range of variations of growth and puberty in pediatric endocrine practice
from 14.00 to 15.00 CEST
14.00–14.05 Pre-webinar survey - Participants
14.05–14.13 Introduction and aim of webinar - Chair: M.O. Savage (UK)
14.13–14.38 Awareness of CPP within the range of variations of growth and puberty in pediatric endocrine practice - Presenter: Sasha Howard (UK)
14.38–14.50 Panel discussion - Chair/Presenter/Participants
14.50–14.55 Post-webinar survey - Participants
14.55–15.00 Closing remarks - Chair: M.O. Savage (UK)
Early identification of CPP patients requiring GnRH analogue therapy
from 14.00 to 15.00 CEST
14.00–14.05 Pre-webinar survey - Participants
14.05–14.13 Introduction and aim of webinar - Chair: M.O. Savage (UK)
14.143–14.38 Early identification of CPP patients requiring GnRH analogue therapy - Presenter: Anders Juul (Denmark)
14.38–14.50 Panel discussion - Chair/Presenter/Participants
14.50–14.55 Post-webinar survey - Participants
14.55–15.00 Closing remarks - Chair: M.O. Savage (UK)
Choice and initiation of GnRHa therapy for CPP with emphasis on long-acting administration
from 17.00 to 18.00 CET
17.00–17.05 Pre-webinar survey - Participants
17.05–17.13 Introduction and aim of webinar - Chair: M.O. Savage (UK)
17.13–17.38 Choice and initiation of GnRHa therapy for CPP with emphasis on long-acting administration - Presenter: Karen Klein (USA)
17.38–17.50 Panel discussion - Chair/Presenter/Participants
17.50–17.55 Post-webinar survey - Participants
17.55–18.00 Closing remarks - Chair: M.O. Savage (UK)